Azilsartan medoxomil/chlorthalidone combination therapy: new prospects in light of SPRINT, HOPE-3 and ACCORDION trials

Cover Page

Cite item

Full Text

Abstract

The results of several large trials (НОРЕ-3, ACCORDION and SPRINT) proved the usefulness of tight control of blood pressure in patients at moderate and high risk for cardiovascular complications, for successful cardiovascular risk management and the importance of early combination antihypertensive therapy. Trials showed the need of dual maximum hypotensive effect combinations with favorable metabolic profile and organ protective potential, such as azilsartan-chlorthalidone fixed combination.

About the authors

S. V Nedogoda

Volgograd State Medical University of Ministry of Health of the Russian Federation

Email: nedogodasv@rambler.ru
д-р мед. наук, проф., зав каф. терапии и эндокринологии ФУВ ГБОУ ВПО ВолгГМУ 400131, Russian Federation, Volgograd, pl. Pavshikh Bortsov, d. 1

References

  1. Yusuf S, Bosch J et al. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med 2016: p. NEJMoa1600176.
  2. Yusuf S, Lonn E et al. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. N Engl J Med 2016: p. NEJMoa1600177.
  3. Lonn E.M, Bosch J et al. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med 2016; 374 (21): 2009-20.
  4. Wright J.T, Williamson J.D et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015; 22 (373): 2103-16.
  5. Edarbi (azilsartan medoxomil), prescribing information. Deerfield, Ill.: Takeda; February 2011.
  6. FDA approves Edarbi to treat hypertension. February 25, 2011. Available at: www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm244722.htm. Accessed May 4, 2011.
  7. Sica D, White W et al. Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring. J Clin Hypertens 2011; 13: 467-72.
  8. White W.B, Weber M.A et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011; 57 (3): 413-20.
  9. Bakris G.L, Sica D et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens 2011; 13 (2): 81-8.
  10. Rakugi H, Enya K, Sugiura K et al. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double - blind clinical study. Hypertens Res 2012; 35 (5): 552-8.
  11. Bönner G, Bakris G et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin - converting enzyme inhibitor ramipril. J Hum Hypertens 2013; 27 (8): 479-86.
  12. Bönner G, Bakris G.L et al. Comparison of antihypertensive efficacy of the new angiotensin receptor blocker azilsartan medoxomil with ramipril. J Hypertens 2010; 28: 283.
  13. Kusuyama T, Ogata H et al. Effects of Azilsartan Compared to Other Angiotensin Receptor Blockers on Left Ventricular Hypertrophy and the Sympathetic Nervous System in Hemodialysis Patients. Therapeutic Apheresis and Dialysis 2014; 18 (5): 398-403.
  14. Smith D.H. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs 2008; 68 (9): 1207-25.
  15. Kusumoto K, Igata H et al. Antihypertensive, insulin - sensitising and renoprotective effects of a novel, potent and long - acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models. Eur J Pharmacol 2011; 669 (1): 84-93.
  16. Iwanami J, Tsukuda K et al. Amelioration of cognitive impairment in the type-2 diabetic mouse by the angiotensin II type-1 receptor blocker candesartan. Hypertension 2007; 50 (6): 1099-105.
  17. Zhao M, Li Y et al. Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats. Diabetes Obes and Metab 2011; 13 (12): 1123-9.
  18. French C.J, Zaman A.T et al. The angiotensin receptor blocker, azilsartan medoxomil (TAK-491), suppresses vascular wall expression of plasminogen activator inhibitor type-I protein potentially facilitating the stabilization of atherosclerotic plaques. J Cardiovasc Pharmacol 2011; 58 (2): 143-8.
  19. Cushman W.C, Bakris G.L et al. Azilsartan Medoxomil Plus Chlorthalidone Reduces Blood Pressure More Effectively Than Olmesartan Plus Hydrochlorothiazide in Stage 2 Systolic Hypertension. Hypertension 2012; 60: 310-8.
  20. Cushman W.C, Bakris G.L et al. Azilsartan medoxomil/chlorthalidone fixed - dose combination lowers BP more than olmesartan/ hydrochlorthalidone fixed - dose combination in stage 2 systolic hypertension. J Hypertens 2011; 29: 118.
  21. Dorsch M.P, Gillespie B.W et al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide a retrospective cohort analysis. Hypertension 2011; 57 (4): 689-94.
  22. Bakris G, Sica D et al. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med 2012; 125: 1229e1-1229.e10.
  23. Kurtz T.W. Chlorthalidone: don’t call it “thiazide - like” anymore. Hypertension 2010; 56: 335-7.
  24. Carter B.L, Ernst M.E et al. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004; 43: 4-9.
  25. Peterzan M.A, Hardy R et al. Meta - analysis of dose - response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension 2012; 59: 1104-9.
  26. Greathouse M. Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension. Vascular health and risk management. 2006; 4: 401.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).